-
Ajinomoto Appoints VP of Sales & Marketing
pharmatimes
April 04, 2019
Ajinomoto Bio-Pharma Services, a global provider of bio-pharmaceutical contract development and manufacturing services, has appointed Jean-Baptiste Agnus as vice president of sales and marketing.
-
The AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
worldpharmanews
April 02, 2019
AveXis further expanding AveXis' production capacity as it prepares to launch Zolgensma®...
-
Envigo Launches PATHWAY
contractpharma
March 13, 2019
Envigo has launched PATHWAY, an integrated solution designed to optimize non-clinical safety assessment programs to enable first-in-human clinical trials.
-
Fujifilm grabs Biogen biologics plant in Europe to bolster its CDMO business
fiercepharma
March 13, 2019
Biogen will open brand-new biologics facilities in Switzerland and has decided it no longer needs its older operations in Denmark.
-
FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin)
worldpharmanews
January 22, 2019
Roche announced that the US Food and Drug Administration has accepted the company's supplemental Biologics License Application for Tecentriq
-
AZ appoints controversial doctor to lead new oncology unit
pharmaphorum
January 09, 2019
AstraZeneca has a new and controversial oncology head after the departure of two key leaders led to a management reshuffle....
-
Roquette & Thermo Fisher Enter Distribution Deal
contractpharma
December 21, 2018
Roquette and Thermo Fisher Scientific have entered a distribution rights agreement for the Roquette portfolio of pharmaceutical ingredients in the United States and Canada to support the high growth potential in these markets.
-
FDA releases Guidance for Industry on Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
americanpharmaceuticalreview
December 20, 2018
FDA is announcing the availability of a revised guidance for industry entitled “Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics.”......
-
Lilly's Taltz beats out AbbVie's megadrug Humira in psoriatic arthritis showdown
fiercepharma
December 19, 2018
What’s a surefire way to get noticed in any field? Beat out a behemoth. And that’s what Eli Lilly’s Taltz has just done in psoriatic arthritis (PsA).
-
WuXi Biologics, ABL Bio Enter Development Deal
contractpharma
November 30, 2018
WuXi Biologics and ABL Bio Corporation have entered into an exclusive development and clinical manufacturing partnership for up to 8 antibody therapeutics including ABL Bio’s biologics pipelines and collaboration programs between...